Guangzhou Baiyunshan Pharmaceutical Holdings Company (874) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 was RMB 22.47 billion, down 2.06% year-over-year from RMB 22.95 billion.

• Net profit attributable to shareholders was RMB 1.82 billion, a 6.99% decrease compared to Q1 2024.

• Net cash flow from operating activities was negative RMB 3.90 billion, a further decline from negative RMB 3.14 billion in Q1 2024.

Financial highlights

• Operating income: RMB 22.47 billion, down 2.06% year-over-year.

• Net profit attributable to shareholders: RMB 1.82 billion, down 6.99% year-over-year.

• Basic and diluted EPS: RMB 1.120, down from RMB 1.204 in Q1 2024.

• Total assets at March 31, 2025: RMB 80.05 billion, down from RMB 81.68 billion at year-end 2024.

• Total equity attributable to shareholders: RMB 37.72 billion, up from RMB 35.90 billion at year-end 2024.

Key financial ratios and metrics

• Weighted average return on net assets: 4.95%, down 0.5 percentage points year-over-year.

• Net profit margin (attributable to shareholders): 8.1% for Q1 2025.

• Operating profit: RMB 2.23 billion, down from RMB 2.45 billion in Q1 2024.

• Total comprehensive income attributable to shareholders: RMB 1.81 billion, down from RMB 1.96 billion.